Shares of Sutro Biopharma Inc (NASDAQ:STRO) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $22.75.
A number of research firms have weighed in on STRO. Zacks Investment Research upgraded Sutro Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, June 13th. HC Wainwright set a $18.00 price target on Sutro Biopharma and gave the stock a “buy” rating in a research note on Monday. ValuEngine upgraded Sutro Biopharma from a “hold” rating to a “buy” rating in a research note on Friday, April 5th. Finally, Cowen restated a “buy” rating on shares of Sutro Biopharma in a research note on Sunday, June 16th.
Shares of STRO stock traded up $0.24 during midday trading on Friday, reaching $11.58. 1,400 shares of the stock were exchanged, compared to its average volume of 60,815. Sutro Biopharma has a 1 year low of $8.50 and a 1 year high of $15.90. The company has a 50 day simple moving average of $11.14. The firm has a market cap of $264.10 million and a price-to-earnings ratio of -1.89.
Several institutional investors have recently bought and sold shares of the stock. American International Group Inc. purchased a new stake in shares of Sutro Biopharma in the 4th quarter worth approximately $38,000. Jennison Associates LLC grew its stake in shares of Sutro Biopharma by 3.6% in the 1st quarter. Jennison Associates LLC now owns 137,788 shares of the company’s stock worth $1,569,000 after buying an additional 4,741 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Sutro Biopharma by 40.6% in the 1st quarter. SG Americas Securities LLC now owns 26,380 shares of the company’s stock worth $300,000 after buying an additional 7,619 shares during the last quarter. Deutsche Bank AG purchased a new stake in shares of Sutro Biopharma in the 4th quarter worth approximately $87,000. Finally, Spark Investment Management LLC purchased a new stake in shares of Sutro Biopharma in the 1st quarter worth approximately $168,000. Institutional investors own 49.00% of the company’s stock.
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
Featured Story: What is a management fee?
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.